# ![@MAIABiotech Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1275228228689387520.png) @MAIABiotech MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. posts on X about $maia, data, ceo, release the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1275228228689387520/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1275228228689387520/c:line/m:interactions.svg)

- [--] Week [---] -77%
- [--] Month [-----] +53%
- [--] Months [------] +5.20%
- [--] Year [------] -56%

### Mentions: [--] [#](/creator/twitter::1275228228689387520/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1275228228689387520/c:line/m:posts_active.svg)

- [--] Month [--] +417%
- [--] Months [--] +8%
- [--] Year [--] -4.50%

### Followers: [---] [#](/creator/twitter::1275228228689387520/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1275228228689387520/c:line/m:followers.svg)

- [--] Week [---] +0.33%
- [--] Month [---] +2.90%
- [--] Months [---] +11%
- [--] Year [---] +18%

### CreatorRank: [---------] [#](/creator/twitter::1275228228689387520/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1275228228689387520/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  100% [finance](/list/finance)  10% [countries](/list/countries)  5% [travel destinations](/list/travel-destinations)  2% [exchanges](/list/exchanges)  1%

**Social topic influence**
[$maia](/topic/$maia) #1, [data](/topic/data) 15%, [ceo](/topic/ceo) 13%, [release](/topic/release) 8%, [in the](/topic/in-the) 7%, [agent](/topic/agent) 5%, [strong](/topic/strong) 4%, [the first](/topic/the-first) 3%, [market](/topic/market) 3%, [space](/topic/space) 2%

**Top accounts mentioned or mentioned by**
[@targetedonc](/creator/undefined) [@myesmo](/creator/undefined) [@iaslc](/creator/undefined) [@benzinga](/creator/undefined) [@cromospharma](/creator/undefined) [@ascopost](/creator/undefined) [@cancernetwrk](/creator/undefined) [@nyse](/creator/undefined) [@sabrinaserani](/creator/undefined) [@biobosspodcast](/creator/undefined) [@asco](/creator/undefined) [@aacrncieortc](/creator/undefined) [@iambiotech](/creator/undefined) [@febsnews](/creator/undefined) [@cellsmdpi](/creator/undefined) [@paulkel79325304](/creator/undefined)

**Top assets mentioned**
[MAIA Biotechnology, Inc. (MAIA)](/topic/$maia)
### Top Social Posts
Top posts by engagements in the last [--] hours

"MAIA to initiate new digital asset treasury strategy focused on top-tier #cryptocurrency assets diversifying our investment portfolio with leading and dynamic #crypto tokens in the rapidly evolving #blockchain space. Read the press release: $MAIA https://bit.ly/4o3y50p https://bit.ly/4o3y50p"  
[X Link](https://x.com/MAIABiotech/status/1975571226207609235)  2025-10-07T14:37Z [---] followers, [----] engagements


"MAIA Biotechnology to begin screening patients in Romania for the expansion phase of its THIO-101 Phase [--] clinical trial. CEO Dr. Vlad Vitoc comments that this expansion is rewarding for several reasons. Read the release: $MAIA #Biotech #NSCLC https://bit.ly/4pl67y0 https://bit.ly/4pl67y0"  
[X Link](https://x.com/anyuser/status/1993334043824304411)  2025-11-25T15:00Z [---] followers, [---] engagements


"MAIA is targeting the $50B immunotherapy market's gap: advanced NSCLC patients who are CPI/chemo-refractory. Ateganosine our telomere-targeting agent is a novel pathway for this population. Phase [--] THIO-104 initiated after FDA Fast Track. $MAIA https://bit.ly/4q6zNzs https://bit.ly/4q6zNzs"  
[X Link](https://x.com/anyuser/status/1998837181318627553)  2025-12-10T19:28Z [---] followers, [---] engagements


"MAIA achieves a key milestone the first patient dosed in the THIO-104 phase [--] pivotal trial. This trial evaluates ateganosine sequenced with a CPI as a third-line treatment for advanced NSCLC patients who are CPI/chemo-resistant. Read the release: $MAIA https://bit.ly/4prIy77 https://bit.ly/4prIy77"  
[X Link](https://x.com/anyuser/status/1999139995768991817)  2025-12-11T15:31Z [---] followers, [---] engagements


"First patient dosed in THIO-104 MAIAs pivotal Phase [--] trial for ateganosine in third-line NSCLC. FDA Fast Track designated; global enrollment active. Get the details: $MAIA https://bit.ly/4prIy77 https://bit.ly/4prIy77"  
[X Link](https://x.com/anyuser/status/2005640101859074520)  2025-12-29T14:00Z [---] followers, [----] engagements


"MAIA highlights progress and priorities for [----] including FDA Fast Track designation for ateganosine in NSCLC and concurrent Phase 2/3 trials advancing toward key clinical milestones. Read more here: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"  
[X Link](https://x.com/MAIABiotech/status/2013651121684779464)  2026-01-20T16:33Z [---] followers, [---] engagements


"FDA Fast Track designation remains a key part of MAIAs ateganosine strategy enabling continued dialogue as late-stage clinical trials progress. Details: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"  
[X Link](https://x.com/MAIABiotech/status/2016889173798486189)  2026-01-29T15:00Z [---] followers, [----] engagements


"MAIA highlights ongoing momentum of ateganosine clinical program at #SITC2025. The posters focus on the ongoing Phase [--] THIO-101 expansion and Phase [--] THIO-104 clinical trials of its first-in-class ateganosine treatment for #NSCLC. Read more: $MAIA https://bit.ly/3XG3ta6 https://bit.ly/3XG3ta6"  
[X Link](https://x.com/anyuser/status/1991877408161460604)  2025-11-21T14:32Z [---] followers, [---] engagements


"It was a privilege to return to #SITC2025 and highlight Phase [--] THIO-101 and Phase [--] THIO-104 clinical trials of our first-in-class small molecule telomere targeting agent ateganosine as a treatment for #NSCLC. $MAIA https://bit.ly/3XG3ta6 https://bit.ly/3XG3ta6"  
[X Link](https://x.com/anyuser/status/1995508362369257927)  2025-12-01T15:00Z [---] followers, [---] engagements


"MAIA Biotechnology Announces Open Market Purchases by CEO and Directors. Read the press release: $MAIA https://bit.ly/48AmY9s https://bit.ly/48AmY9s"  
[X Link](https://x.com/anyuser/status/1995536126707155231)  2025-12-01T16:51Z [---] followers, [---] engagements


"MAIAs emerging clinical results continue to surpass expectations. Ateganosine advances toward Phase [--] as the only direct telomere-targeting anticancer agent currently in clinical development anywhere. Full release: $MAIA https://bit.ly/48J7UpW https://bit.ly/48J7UpW"  
[X Link](https://x.com/anyuser/status/1999197732611768794)  2025-12-11T19:20Z [---] followers, [---] engagements


"In case you missed it: MAIA's Phase [--] program reached a key milestone with the first patient dosed in our pivotal trial. Progress towards FDA approval underway. Details: $MAIA https://bit.ly/4prIy77 https://bit.ly/4prIy77"  
[X Link](https://x.com/anyuser/status/2001714233273114927)  2025-12-18T18:00Z [---] followers, [---] engagements


"MAIA's ateganosine is a first-in-class telomere-targeting agent that exploits a universal cancer feature. Its dual mechanism triggers cancer cell death and activates immune response. Phase [--] THIO-104 has begun under FDA Fast Track. Full release: $MAIA https://bit.ly/48J7UpW https://bit.ly/48J7UpW"  
[X Link](https://x.com/anyuser/status/2003103429413986734)  2025-12-22T14:00Z [---] followers, [---] engagements


"The $34.1B NSCLC market projected to double is ready for disruption. $MAIA is positioned with ateganosine to capture value in the CPI-refractory population. Commercial opportunity spans Glioblastoma HCC and SCLC backed by FDA ODDs. View our strategy: https://bit.ly/4q6zNzs https://bit.ly/4q6zNzs"  
[X Link](https://x.com/anyuser/status/2003465771863683246)  2025-12-23T14:00Z [---] followers, [---] engagements


"MAIAs leadership continues to demonstrate a unified stance. Recent insider buying in [----] demonstrates confidence in the companys strategy ateganosines growing body of clinical evidence and the opportunity ahead. ICYMI: $MAIA https://bit.ly/4a5p1od https://bit.ly/4a5p1od"  
[X Link](https://x.com/anyuser/status/2004552935447908387)  2025-12-26T14:00Z [---] followers, [----] engagements


"Only telomere-targeting agent in clinical development: ateganosine begins pivotal Phase [--] trial for advanced NSCLC with statistical models showing high probability of technical success for regulatory approval. $MAIA https://bit.ly/48J7UpW https://bit.ly/48J7UpW"  
[X Link](https://x.com/anyuser/status/2008176785976951208)  2026-01-05T14:00Z [---] followers, [----] engagements


"Ateganosine remains the only direct telomere-targeting therapy in clinical development for NSCLC. MAIA continues to leverage its differentiated approach while preparing second-generation molecules for clinical evaluation. Learn more: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"  
[X Link](https://x.com/anyuser/status/2014714910857433430)  2026-01-23T15:00Z [---] followers, [----] engagements


"Late-stage clinical development continues at MAIA. Ateganosine is advancing through a pivotal Phase [--] trial alongside an expanded Phase [--] study in NSCLC with multiple data readouts expected to inform next regulatory steps. Learn more: $MAIA https://bit.ly/4r1SDYG https://bit.ly/4r1SDYG"  
[X Link](https://x.com/anyuser/status/2015802050739687743)  2026-01-26T15:00Z [---] followers, [----] engagements


"On #WorldCancerDay we recognize the patients and families affected by cancer. MAIAs ateganosine is an investigational therapy in late-stage trials for NSCLC. Learn more: $MAIA https://maiabiotech.com/pipeline/thio/ https://maiabiotech.com/pipeline/thio/"  
[X Link](https://x.com/anyuser/status/2019068245135798375)  2026-02-04T15:19Z [---] followers, [---] engagements


"Dr. Vitocs presentation at #BIO2024 highlighting our Phase [--] THIO-101 #clinicaltrial is scheduled for 6/5 at 11:30am PT in Theater [--]. He will also be available for meetings. Interested parties can submit a request here: $MAIA https://bit.ly/2EJf14tb https://bit.ly/2EJf14tb"  
[X Link](https://x.com/MAIABiotech/status/1793656155572470096)  2024-05-23T14:52Z [---] followers, [---] engagements


"MAIA looks forward to revealing the newest efficacy results from THIO-101 and discussing our pioneering telomere targeting science underlying THIO. Our poster will be presented on 6/3 at 1:30pm CT. More information here: https://bit.ly/4dL9ngY https://bit.ly/4dL9ngY"  
[X Link](https://x.com/MAIABiotech/status/1795842562722287655)  2024-05-29T15:40Z [---] followers, [----] engagements


"CEO Vlad Vitoc M.D. will deliver a presentation at #BIO2024 on 6/5 at 11:30am PT featuring up-to-date findings from our Phase [--] THIO-101 #clinicaltrial evaluating THIO sequenced with the immune CPI cemiplimab (Libtayo) in advanced #NSCLC. More: $MAIA https://bit.ly/3wLD0hy https://bit.ly/3wLD0hy"  
[X Link](https://x.com/MAIABiotech/status/1796194959898390656)  2024-05-30T15:00Z [---] followers, [---] engagements


"#ASCO24 has begun The MAIA team is having a productive first day and our CEO Vlad Vitoc is holding meetings with KOLs. Make sure to stop by our poster presentation in the #NSCLC Metastatic session on Monday 6/3 1:30 - 4:30pm CT in Hall A at Board [---] - Abstract [----]. $MAIA"  
[X Link](https://x.com/MAIABiotech/status/1796633927169302914)  2024-05-31T20:04Z [---] followers, [----] engagements


"Today at 1:30pm CT MAIAs poster presentation revealing new efficacy data from Phase [--] THIO-101 trial in #NSCLC will be presented at #ASCO24. It is also available on our website here: $MAIA https://bit.ly/4bI0wuC https://bit.ly/4bI0wuC"  
[X Link](https://x.com/MAIABiotech/status/1797621790270771395)  2024-06-03T13:30Z [---] followers, [----] engagements


"Don't miss our poster presentation today at 1:30pm CT at #ASCO24 Board [---] Abstract [----] We're looking forward to sharing the latest data from our Phase [--] THIO-101 clinical trial for patients with advanced #NSCLC. See you there Details: $MAIA https://bit.ly/4dL9ngY https://bit.ly/4dL9ngY"  
[X Link](https://x.com/MAIABiotech/status/1797665290177699864)  2024-06-03T16:22Z [---] followers, [----] engagements


"MAIA Biotechnology Reveals New #Clinical Data Showing THIOs Strong Efficacy in Non-Small Cell Lung Cancer. Read the press release here: $MAIA #NSCLC #Oncology #ASCO24 https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"  
[X Link](https://x.com/MAIABiotech/status/1798010722561282242)  2024-06-04T15:15Z [---] followers, [----] engagements


"Today at 11:30am PT Dr. Vitoc is presenting at #BIO2024 to highlight findings from MAIAs Phase [--] THIO-101 clinical trial evaluating THIO our telomere-targeting agent in #NSCLC patients. Hope to see you there $MAIA"  
[X Link](https://x.com/MAIABiotech/status/1798346571848753380)  2024-06-05T13:30Z [---] followers, [----] engagements


"MAIA announced new efficacy data from our Phase [--] THIO-101 #clinicaltrial evaluating THIO in patients with #NSCLC greatly surpassing the standard-of-care with ORR of 38% and DCR of 85% in third-line treatment. Dive into the press release: $MAIA #ASCO24 https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"  
[X Link](https://x.com/MAIABiotech/status/1798350344268738824)  2024-06-05T13:45Z [---] followers, [----] engagements


"New efficacy data from MAIAs Phase [--] THIO-101 #clinicaltrial in patients with advanced #NSCLC shows an ORR of 38% and a DCR of 85% exceeding the current standard-of-care in third-line treatment. Read the press release here: $MAIA #Oncology #ASCO24 https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"  
[X Link](https://x.com/MAIABiotech/status/1798708958003442083)  2024-06-06T13:30Z [---] followers, [---] engagements


"MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent. Read the press release here: $MAIA #Biopharma #NSCLC #Immunotherapy https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"  
[X Link](https://x.com/MAIABiotech/status/1798720107566301397)  2024-06-06T14:14Z [---] followers, 10.8K engagements


"New from @Benzinga: New Clinical Data Reveals MAIA Biotechnologys THIO Achieves High Efficacy In Advanced #NSCLC Treatment. Dive into the article here: $MAIA #Biotech #Immunotherapies https://bit.ly/3XbgXfe https://bit.ly/3XbgXfe"  
[X Link](https://x.com/MAIABiotech/status/1798733422732730599)  2024-06-06T15:07Z [---] followers, [---] engagements


"Today MAIA announced key achievements year-to-date including recent #clinical progress for lead candidate THIO a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in #NSCLC. Read: $MAIA https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"  
[X Link](https://x.com/MAIABiotech/status/1798746063634866278)  2024-06-06T15:57Z [---] followers, [----] engagements


"New clinical data shows THIOs strong efficacy in #NSCLC patients with ORR of 38% and DCR of 85% in third-line treatment surpassing the current standard-of-care. Read MAIAs press release for highlights on the results: $MAIA #ClinicalResearch #Oncology https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"  
[X Link](https://x.com/MAIABiotech/status/1799071351958847866)  2024-06-07T13:30Z [---] followers, [---] engagements


"MAIAs newest data shows THIOs strong outperformance against standard-of-care treatments in #NSCLC. THIO-101 clinical data showed: ORR of 38% DCR of 85% Dive into the press release: $MAIA #ClinicalResearch #CancerResearch https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"  
[X Link](https://x.com/MAIABiotech/status/1799116047775158548)  2024-06-07T16:27Z [---] followers, [---] engagements


"Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable By Fdas Approval Of A Telomerase Inhibitor Agent Therapy. Read the press release here: $MAIA #Biopharma #CancerResearch https://bit.ly/4aR8Wz9 https://bit.ly/4aR8Wz9"  
[X Link](https://x.com/MAIABiotech/status/1799122691460358199)  2024-06-07T16:54Z [---] followers, [----] engagements


"MAIA is developing telomere-targeting #immunotherapies for cancer treatment. Recent promising new clinical data has unveiled efficacy of our lead product candidate THIO in treating #NSCLC. Read more about our key findings here: $MAIA #Oncology https://bit.ly/3XbgXfe https://bit.ly/3XbgXfe"  
[X Link](https://x.com/MAIABiotech/status/1799135495093444625)  2024-06-07T17:45Z [---] followers, [---] engagements


"Our most recent #clinical data points to THIOs unprecedented DCR of 85% ORR of 38% and post-therapy patient benefits. Third-line treatment with THIO has far outperformed reported standard-of-care data in #NSCLC. Read our latest news: $MAIA #Oncology https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"  
[X Link](https://x.com/MAIABiotech/status/1800158510514086250)  2024-06-10T13:30Z [---] followers, [----] engagements


"MAIA and @CromosPharma are part of an innovative collaboration to advance cancer treatment focused on THIO a groundbreaking telomere-targeting agent for #NSCLC. Read the news here: $MAIA #ASCO2024 https://bit.ly/3XAFUkg https://bit.ly/3XAFUkg"  
[X Link](https://x.com/MAIABiotech/status/1805287971748213221)  2024-06-24T17:12Z [---] followers, [----] engagements


"Pleased to share that Dr. Jankowski the presenting author of MAIAs poster at #ASCO24 and key investigator in our Phase [--] #clinicaltrial was selected as one of the very few authors to provide a video update. Watch his discussion via @ASCOPost: $MAIA https://bit.ly/3RExJja https://bit.ly/3RExJja"  
[X Link](https://x.com/MAIABiotech/status/1805629918740353157)  2024-06-25T15:51Z [---] followers, [---] engagements


"#ASCO24 recap MAIA had a productive time networking exploring exhibits and presenting new clinical data in a poster session showing THIOs strong efficacy in #NSCLC. Watch below. $MAIA"  
[X Link](https://x.com/MAIABiotech/status/1805956854335345120)  2024-06-26T13:30Z [---] followers, [----] engagements


"Discover new efficacy data from MAIAs Phase [--] THIO-101 #clinicaltrial evaluating THIO sequenced with the immune CPI cemiplimab (Libtayo) in patients with advanced #NSCLC: $MAIA https://bit.ly/4aMMFlZ https://bit.ly/4aMMFlZ"  
[X Link](https://x.com/MAIABiotech/status/1811026367628050810)  2024-07-10T13:15Z [---] followers, [----] engagements


"MAIA Biotechnology Announces New Updates from Phase [--] Trial of Novel Cancer Treatment Agent. Read the press release here: $MAIA #Biopharma #NSCLC #Immunotherapy https://bit.ly/4cP1AOD https://bit.ly/4cP1AOD"  
[X Link](https://x.com/MAIABiotech/status/1815742684625051839)  2024-07-23T13:36Z [---] followers, [----] engagements


"MAIA announced positive treatment updates from its Phase [--] clinical trial THIO-101 evaluating THIO in patients with advanced #NSCLC. Read the press release here: $MAIA #Biotech #ClinicalResearch https://bit.ly/4cP1AOD https://bit.ly/4cP1AOD"  
[X Link](https://x.com/MAIABiotech/status/1816107359682306359)  2024-07-24T13:45Z [---] followers, [---] engagements


"Telomere-Targeting Agent Demonstrates Tolerability in Advanced #NSCLC. Read more about our latest news via @CancerNetwrk here: $MAIA #Biotechnology https://bit.ly/3A5nb6D https://bit.ly/3A5nb6D"  
[X Link](https://x.com/MAIABiotech/status/1816137784458871267)  2024-07-24T15:46Z [---] followers, [---] engagements


"Ongoing benefits of THIO in longer-term patients are particularly notable signifying THIOs potential as a durable and efficacious treatment for advanced #NSCLC patients. Read the latest clinical updates from our Phase [--] #clinicaltrial of THIO-101: $MAIA https://bit.ly/4cP1AOD https://bit.ly/4cP1AOD"  
[X Link](https://x.com/MAIABiotech/status/1816469731781595415)  2024-07-25T13:45Z [---] followers, [----] engagements


"#ICYMI: MAIA recently released key achievements year-to-date including #clinical progress for lead candidate THIO a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in #NSCLC. Read more: $MAIA https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"  
[X Link](https://x.com/MAIABiotech/status/1816837152317067749)  2024-07-26T14:05Z [---] followers, [---] engagements


"#OnThisDay two years ago MAIA listed on the @NYSE. This milestone reflects our dedication to #clinicalresearch for our lead candidate in development THIO a telomere targeting agent that has shown exceptional efficacy on patients in NSCLC. $MAIA #NYSE #Biotech #Innovation"  
[X Link](https://x.com/MAIABiotech/status/1817610807800160732)  2024-07-28T17:19Z [---] followers, [----] engagements


"MAIAs recent #clinical data points to THIOs unprecedented DCR of 85% ORR of 38% and post-therapy patient benefits. Third-line treatment with THIO has far outperformed reported standard-of-care data in #NSCLC. If you missed it read here: $MAIA https://bit.ly/4bNqiy7 https://bit.ly/4bNqiy7"  
[X Link](https://x.com/MAIABiotech/status/1818638265525637324)  2024-07-31T13:22Z [---] followers, [---] engagements


"THIO Shows Lower Toxicity Than Standard Treatments in #NSCLC Study. Read more about our phase [--] trial that shows the treatment has been well-tolerated and demonstrates lower rates of toxicity by @sabrinaserani via @TargetedOnc here: $MAIA #Biotechnology https://bit.ly/3SrI4PR https://bit.ly/3SrI4PR"  
[X Link](https://x.com/MAIABiotech/status/1819002663062638659)  2024-08-01T13:30Z [---] followers, [----] engagements


"MAIA Biotechnology to Initiate Phase [--] Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients. Read the press release here: $MAIA #Biotech #Oncology #NSCLC https://bit.ly/4kjYJ4o https://bit.ly/4kjYJ4o"  
[X Link](https://x.com/MAIABiotech/status/1895129929961931118)  2025-02-27T15:12Z [---] followers, [---] engagements


"Following successful outcomes to date in THIO-101 the expansion of the study will assess ORR in advanced NSCLC patients receiving 3L therapy who were resistant to previous CPI and chemotherapy. Missed the announcement Read: $MAIA https://bit.ly/4i0lvfV https://bit.ly/4i0lvfV"  
[X Link](https://x.com/MAIABiotech/status/1895481624524968318)  2025-02-28T14:30Z [---] followers, [---] engagements


"MAIA has announced plans to initiate a Phase [--] pivotal trial in [----] named THIO-104 to evaluate the efficacy of THIO administered in sequence with a CPI in 3L #NSCLC patients who are resistant to checkpoint inhibitors and chemotherapy. $MAIA #Oncology https://bit.ly/4kjYJ4o https://bit.ly/4kjYJ4o"  
[X Link](https://x.com/MAIABiotech/status/1895500576521142452)  2025-02-28T15:45Z [---] followers, [---] engagements


"MAIA CEO Vlad Vitoc shares his insights with @BioBossPodcast about leadership in #biopharma and how MAIA is working to develop and deliver innovative medicines to improve and extend the lives of people living with cancer. Tune in: $MAIA #Biotech #Oncology https://bit.ly/4kjJUhY https://bit.ly/4kjJUhY"  
[X Link](https://x.com/MAIABiotech/status/1896598988234649756)  2025-03-03T16:30Z [---] followers, [---] engagements


"MAIA Biotechnology Receives USAN Council Approval for Ateganosine as Nonproprietary (Generic) Name for Anticancer Agent THIO. Read the press release here: $MAIA #Biotech #NSCLC https://bit.ly/43YNsAz https://bit.ly/43YNsAz"  
[X Link](https://x.com/MAIABiotech/status/1902383332844822590)  2025-03-19T15:35Z [---] followers, [---] engagements


"MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug. Read the press release here: $MAIA #Biotech https://bit.ly/4htADBr https://bit.ly/4htADBr"  
[X Link](https://x.com/MAIABiotech/status/1902762674976592017)  2025-03-20T16:42Z [---] followers, [----] engagements


""The designation of a new nonproprietary name for THIO is a key step along our development and regulatory pathway as we move forward with Phase [--] and [--] clinical trials said CEO Vlad Vitoc M.D. ICYMI read the announcement: $MAIA #Biotech https://bit.ly/43YNsAz https://bit.ly/43YNsAz"  
[X Link](https://x.com/MAIABiotech/status/1903076677019902374)  2025-03-21T13:30Z [---] followers, [---] engagements


"MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress (ELCC) [----]. Read the press release here: $MAIA @myESMO #ELCC25 https://bit.ly/4cbQwvq https://bit.ly/4cbQwvq"  
[X Link](https://x.com/MAIABiotech/status/1904541914461839547)  2025-03-25T14:32Z [---] followers, [---] engagements


"MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in [----] Letter to Shareholders. Read the press release here: $MAIA #Biotech #NSCLC https://bit.ly/4iQiX4D https://bit.ly/4iQiX4D"  
[X Link](https://x.com/MAIABiotech/status/1907069565667827783)  2025-04-01T13:56Z [---] followers, [---] engagements


"MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (@ASCO) [----] Annual Meeting. Read the press release: $MAIA #Oncology #Biotech #ASCO25 https://bit.ly/3S6aEpr https://bit.ly/3S6aEpr"  
[X Link](https://x.com/MAIABiotech/status/1923123017413959881)  2025-05-15T21:07Z [---] followers, [---] engagements


"MAIA announces positive efficacy update for Phase [--] THIO-101 #clinicaltrial in #NSCLC. Read the press release: $MAIA #Biotech https://bit.ly/4dNxxrT https://bit.ly/4dNxxrT"  
[X Link](https://x.com/MAIABiotech/status/1930624739728314795)  2025-06-05T13:56Z [---] followers, [---] engagements


"MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase [--] Clinical Trial. Read the press release here: $MAIA #Biotech #NSCLC https://bit.ly/4kTkzLw https://bit.ly/4kTkzLw"  
[X Link](https://x.com/MAIABiotech/status/1930644441393414583)  2025-06-05T15:14Z [---] followers, [---] engagements


"MAIA is pleased to announce a master clinical supply agreement with Roche for hard-to-treat cancer therapies. Read the press release: $MAIA #Immunotherapy #Oncology #Biotech https://bit.ly/43WDFJy https://bit.ly/43WDFJy"  
[X Link](https://x.com/MAIABiotech/status/1935350680367063072)  2025-06-18T14:55Z [---] followers, [---] engagements


"MAIA is planning for a Phase [--] clinical trial in #hepatocellularcarcinoma. With the appointment of our new SAB members they will advise MAIA on designs and protocols for its CST in HCC and may participate in future investigator sponsored trials. $MAIA https://bit.ly/3ZJxw2h https://bit.ly/3ZJxw2h"  
[X Link](https://x.com/MAIABiotech/status/1938307177724203244)  2025-06-26T18:43Z [---] followers, [---] engagements


"MAIA's clinical master supply agreement with Roche supports the evaluation of ateganosine (THIO) in combination with Tecentriq in hard-to-treat cancers. The combination was found to be highly synergistic and effective in #preclinical studies. ICYMI: $MAIA https://bit.ly/3TNcT1F https://bit.ly/3TNcT1F"  
[X Link](https://x.com/MAIABiotech/status/1939707826546323583)  2025-06-30T15:29Z [---] followers, [---] engagements


"MAIA will present two posters at #FEBSCongress2025 featuring our lead telomere-targeting agent and next-generation treatments. Session date and time: July [--] [----] from 12:30pm to 2:30pm TRT. More details are available here: $MAIA #Oncology #Biotech https://bit.ly/4ntzu0N https://bit.ly/4ntzu0N"  
[X Link](https://x.com/MAIABiotech/status/1940765005063881176)  2025-07-03T13:30Z [---] followers, [---] engagements


"MAIA is presenting two posters today at the #FEBS2025Congress Cancer Therapy session 12:30-2:30pm TRT highlighting our lead telomere-targeting agent and next-generation treatments. Poster presentation details available here: $MAIA https://bit.ly/4ntzu0N https://bit.ly/4ntzu0N"  
[X Link](https://x.com/MAIABiotech/status/1942116468163743870)  2025-07-07T07:00Z [---] followers, [---] engagements


"MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase [--] Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer. Read the press release: $MAIA #Biotech #NSCLC https://bit.ly/4nWbgNh https://bit.ly/4nWbgNh"  
[X Link](https://x.com/MAIABiotech/status/1942947880974590377)  2025-07-09T14:04Z [---] followers, [----] engagements


""Ateganosines observed OS in third-line #NSCLC exceeds all known benchmarks. Dr. Vlad Vitoc MAIA CEO. See announcement on our Phase [--] trial expansion: $MAIA #Biotech #Oncology https://bit.ly/4nWbgNh https://bit.ly/4nWbgNh"  
[X Link](https://x.com/MAIABiotech/status/1945838442530709842)  2025-07-17T13:30Z [---] followers, [---] engagements


"MAIA Biotechnology Receives FDAs Fast Track Designation for Ateganosine as a Treatment for #NSCLC. Read the press release: $MAIA #Biotech https://bit.ly/3UvBQPA https://bit.ly/3UvBQPA"  
[X Link](https://x.com/MAIABiotech/status/1949827924955148526)  2025-07-28T13:42Z [---] followers, [---] engagements


"MAIA Biotechnologys investigational telomere-targeting agent ateganosine (THIO) has received FDA Fast Track designation for advanced #NSCLC patients who progressed after checkpoint inhibitor therapy. Read more via @TargetedOnc: $MAIA #Oncology https://bit.ly/4mlUSny https://bit.ly/4mlUSny"  
[X Link](https://x.com/MAIABiotech/status/1950294479153324477)  2025-07-29T20:36Z [---] followers, [---] engagements


"The FDAs Fast Track Designation recognizes ateganosines (THIO) potential as a new therapeutic paradigm in cancer treatment science. Missed the announcement Learn more about our pivotal Phase [--] THIO-101 clinical trial: $MAIA #Biotech https://bit.ly/3UvBQPA https://bit.ly/3UvBQPA"  
[X Link](https://x.com/MAIABiotech/status/1950549490089202004)  2025-07-30T13:30Z [---] followers, [---] engagements


"MAIA is presenting ateganosine (THIO) at @IASLC #WCLC25. 📊 P1.11 - Metastatic NSCLC Immunotherapy 📅Sunday September [--] [----] 🕙10:30 a.m. to 12:00 p.m. CEST 📍Barcelona Spain Poster available at Press Release: $MAIA https://bit.ly/4peqTAc https://bit.ly/48dgkFj https://bit.ly/4peqTAc https://bit.ly/48dgkFj"  
[X Link](https://x.com/MAIABiotech/status/1964599571268370568)  2025-09-07T08:00Z [---] followers, [----] engagements


"MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase [--] Trial of Cancer-Fighting Agent. Read the press release: $MAIA #NSCLC #Biotech #Immunotherapy https://bit.ly/3IG5e3l https://bit.ly/3IG5e3l"  
[X Link](https://x.com/MAIABiotech/status/1970852466892640759)  2025-09-24T14:06Z [---] followers, [---] engagements


"MAIA recently presented a Trial in Progress poster at the [----] @AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Read the press release for more insight on the poster: $MAIA #Targets25 #Oncology #Biotech https://bit.ly/47bS7k0 https://bit.ly/47bS7k0"  
[X Link](https://x.com/MAIABiotech/status/1982845332602929394)  2025-10-27T16:22Z [---] followers, [---] engagements


"MAIA Biotechnology shared updates on its THIO-101 Phase [--] trial at the [----] AACR-NCI-EORTC Conference marking progress in enrollment and international site expansion across Taiwan and Turkey. ICYMI: $MAIA #Targets25 #Oncology #Biotech https://bit.ly/47bS7k0 https://bit.ly/47bS7k0"  
[X Link](https://x.com/MAIABiotech/status/1985716225716920621)  2025-11-04T14:30Z [---] followers, [---] engagements


"MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romanias [----] Smart Diaspora Conference on Oncology Research and Innovation. Read the press release: $MAIA #Oncology #NSCLC https://bit.ly/4pl67y0 https://bit.ly/4pl67y0"  
[X Link](https://x.com/MAIABiotech/status/1991523999210258612)  2025-11-20T15:08Z [---] followers, [---] engagements


"CEO Vlad Vitoc Our initiation of THIO-104 will mark an important milestone along our goal for THIOs FDA commercial approval. ICYMI read the announcement: $MAIA #Biotech #Oncology https://bit.ly/4kjYJ4o https://bit.ly/4kjYJ4o"  
[X Link](https://x.com/MAIABiotech/status/1896938795838124059)  2025-03-04T15:00Z [---] followers, [---] engagements


"Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard #cancertreatments. Preclinical data published in peer-reviewed scientific journal Naunyn-Schmiedeberg's Archives of Pharmacology. $MAIA #Biotech https://bit.ly/4htADBr https://bit.ly/4htADBr"  
[X Link](https://x.com/MAIABiotech/status/1904590416936136884)  2025-03-25T17:45Z [---] followers, [----] engagements


"Interview with the Chairman and CEO of MAIA Vlad Vitoc and The Wall Street Transcript. Learn about his 25+ years of oncology leadership and MAIA's focus on developing targeted immunotherapies for cancer. Users can subscribe here: $MAIA #Oncology #Biotech https://bit.ly/3GxblWf https://bit.ly/3GxblWf"  
[X Link](https://x.com/MAIABiotech/status/1917265384807293157)  2025-04-29T17:11Z [---] followers, [----] engagements


"MAIA Biotechnology Announces Director Participation In Recent Private Placement. Read the press release here: $MAIA https://bit.ly/3S4lZq1 https://bit.ly/3S4lZq1"  
[X Link](https://x.com/MAIABiotech/status/1922677285112484157)  2025-05-14T15:36Z [---] followers, [---] engagements


"MAIAs abstract about efficacy data from the Phase [--] THIO-101 clinical trial was accepted for a poster presentation at #ASCO25 on May [--] [----] from 01:30pm to 04:30pm CDT in the Lung Cancer track. Poster details: $MAIA https://bit.ly/3S6aEpr https://bit.ly/3S6aEpr"  
[X Link](https://x.com/MAIABiotech/status/1924857740930769115)  2025-05-20T16:00Z [---] followers, [---] engagements


"MAIA Biotechnology to Present at BIO International Convention [----] taking place June 16-19 [----] in Boston Massachusetts. Presentation details are available in the press release: $MAIA #BIO2025 @IAmBiotech https://bit.ly/4mZAQjW https://bit.ly/4mZAQjW"  
[X Link](https://x.com/MAIABiotech/status/1932446801107308796)  2025-06-10T14:36Z [---] followers, [---] engagements


"MAIAs CEO is presenting at #BIO2025 on 6/18 at 11:30 AM EDT to present the latest findings from the THIO-101 Phase [--] clinical trial evaluating ateganosine (THIO) sequenced with the immune CPI cemiplimab (Libtayo) in advanced #NSCLC. $MAIA https://bit.ly/4mZAQjW https://bit.ly/4mZAQjW"  
[X Link](https://x.com/MAIABiotech/status/1933233034716688552)  2025-06-12T18:40Z [---] followers, [---] engagements


"Today MAIA will highlight the latest findings from our THIO-101 Phase [--] clinical trial in #NSCLC at #BIO2025 at 11:30 AM EDT. More on our CEOs presentation: $MAIA #Biotech #Oncology https://bit.ly/4mZAQjW https://bit.ly/4mZAQjW"  
[X Link](https://x.com/MAIABiotech/status/1935321742169248059)  2025-06-18T13:00Z [---] followers, [---] engagements


"MAIA Biotechnology is pleased to welcome leading #hepatocellularcarcinoma clinician-scientists to its Scientific Advisory Board. Planning for phase [--] #clinicaltrial in HCC underway. Read the press release: $MAIA #Oncology #Biotech https://bit.ly/3ZJxw2h https://bit.ly/3ZJxw2h"  
[X Link](https://x.com/MAIABiotech/status/1937513856605298737)  2025-06-24T14:11Z [---] followers, [---] engagements


"MAIA Biotechnology to present two posters featuring cancer telomere-targeting agents at @FEBSnews. Read the press release: $MAIA #FEBSCongress2025 #CancerResearch #Oncology #Biotech https://ir.maiabiotech.com/news-events/press-releases/detail/143/maia-biotechnology-to-present-two-posters-featuring-cancer https://ir.maiabiotech.com/news-events/press-releases/detail/143/maia-biotechnology-to-present-two-posters-featuring-cancer"  
[X Link](https://x.com/MAIABiotech/status/1940070041774645329)  2025-07-01T15:28Z [---] followers, [---] engagements


"ICYMI: MAIA has dosed the first patient in Taiwan for the expansion phase of its THIO-101 Phase [--] trial for advanced #NSCLC. This marks a key milestone opening a significantly larger patient pool for evaluation of ateganosine (THIO). $MAIA #Biotechnology https://bit.ly/4nWbgNh https://bit.ly/4nWbgNh"  
[X Link](https://x.com/MAIABiotech/status/1945143264165703943)  2025-07-15T15:27Z [---] followers, [---] engagements


"MAIA recently announced THIO-101 trial data for advanced #NSCLC with median OS of [----] months for third-line patients exceeding known benchmarks. This positions a potential first-mover advantage in a multi-billion-dollar space. $MAIA #Immunotherapy https://bit.ly/4nWbgNh https://bit.ly/4nWbgNh"  
[X Link](https://x.com/MAIABiotech/status/1945476034926665887)  2025-07-16T13:30Z [---] followers, [---] engagements


"MAIA Biotechnology Announced Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy. Read the press release: $MAIA #Biotech #Oncology #ClinicalResearch https://bit.ly/3GQgrgQ https://bit.ly/3GQgrgQ"  
[X Link](https://x.com/MAIABiotech/status/1945853481098572170)  2025-07-17T14:29Z [---] followers, [---] engagements


"MAIA granted Fast Track designation for ateganosine (THIO) for the treatment of #NSCLC. Latest data in pivotal Phase [--] THIO-101 clinical trial shows median OS of [----] months. Read more: $MAIA #Biotech #ClinicalResearch #CancerResearch https://bit.ly/3UvBQPA https://bit.ly/3UvBQPA"  
[X Link](https://x.com/MAIABiotech/status/1952361419157938248)  2025-08-04T13:30Z [---] followers, [---] engagements


"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy. Read the press release: $MAIA #Immunotherapy #Biotech #Biopharma https://bit.ly/4fzA0Hb https://bit.ly/4fzA0Hb"  
[X Link](https://x.com/MAIABiotech/status/1955641992072872151)  2025-08-13T14:45Z [---] followers, [---] engagements


"CEO Vlad Vitoc M.D. on MAIA's European #patent grant: "The new IP is expected to further secure and expand the value of our first-in-class telomere-targeting compounds." Patent covers next-generation telomere-targeting agents for #cancertherapy. $MAIA https://bit.ly/4fzA0Hb https://bit.ly/4fzA0Hb"  
[X Link](https://x.com/MAIABiotech/status/1959971416062734457)  2025-08-25T13:29Z [---] followers, [---] engagements


"MAIA announces publication of interim clinical data detailing developments in its Phase [--] THIO-101 of telomere targeting anticancer agent in peer-reviewed journal @Cells_MDPI. Read the press release: $MAIA #cells_mdpi #CellBiology #Immunotherapy #Biotech https://bit.ly/4lSVssj https://bit.ly/4lSVssj"  
[X Link](https://x.com/MAIABiotech/status/1960706541058716109)  2025-08-27T14:10Z [---] followers, [---] engagements


"MAIAs abstract selected for poster presentation at @IASLC #WCLC25 September [--] in Barcelona Spain. Poster details durability and efficacy of ateganosine (THIO) treatment in NSCLC. Read the press release: $MAIA #LungCancer https://bit.ly/4peqTAc https://bit.ly/4peqTAc"  
[X Link](https://x.com/MAIABiotech/status/1963974094719692984)  2025-09-05T14:34Z [---] followers, [----] engagements


"MAIA highlighted positive efficacy data from its Phase [--] clinical trial THIO-101 evaluating treatment with ateganosine (THIO) sequenced with the immune CPI cemiplimab in patients with advanced #NSCLC. Read the press release: $MAIA #Biotech #OncNews https://bit.ly/46hEQo8 https://bit.ly/46hEQo8"  
[X Link](https://x.com/MAIABiotech/status/1966150888348619083)  2025-09-11T14:44Z [---] followers, [---] engagements


"MAIA is thrilled to have been awarded a prestigious NIH grant to support the expansion of our Phase [--] trial a tremendous achievement due to the dedication and hard work of everyone involved in the clinical development of ateganosine. ICYMI: $MAIA #NSCLC https://bit.ly/3IG5e3l https://bit.ly/3IG5e3l"  
[X Link](https://x.com/MAIABiotech/status/1971632504428802331)  2025-09-26T17:46Z [---] followers, [---] engagements


"Highlights from #ESMO2025: MAIA showcased two e-posters detailing its ongoing Phase [--] and Phase [--] clinical trials of ateganosine in #NSCLC. Details are available in the press release: $MAIA @myESMO #Oncology #Biotech https://bit.ly/43uDnKD https://bit.ly/43uDnKD"  
[X Link](https://x.com/MAIABiotech/status/1981368705377304696)  2025-10-23T14:34Z [---] followers, [---] engagements


"MAIAs Director of Clinical Operations Matthew Failor attended #ESMO2025 meeting with KOLs and oncologists for meaningful discussions about THIO-101 trial expansion and upcoming clinical programs advancing ateganosine (THIO) in #NSCLC. ICYMI: $MAIA https://bit.ly/43uDnKD https://bit.ly/43uDnKD"  
[X Link](https://x.com/MAIABiotech/status/1981747370422337631)  2025-10-24T15:39Z [---] followers, [---] engagements


"MAIA Leadership Continues Insider Buying in [----] and Trial Data Signals Breakout Potential. Read the release: $MAIA https://bit.ly/4a5p1od https://bit.ly/4a5p1od"  
[X Link](https://x.com/anyuser/status/1999132394402529289)  2025-12-11T15:01Z [---] followers, [---] engagements


"NSCLC market poised to nearly double to $68.8B by [----]. MAIAs ateganosine addresses the largest unmet need: patients without actionable mutations or CPI response. Read the release for more information: https://bit.ly/4q6zNzs https://bit.ly/4q6zNzs"  
[X Link](https://x.com/MAIABiotech/status/2007089577182343560)  2026-01-02T14:00Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing